Mind Medicine (MMED – Research Report), the Healthcare company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating, with a $75.00 price target.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -17.7% and a 31.4% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Longboard Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mind Medicine with a C$37.02 average price target.
The company’s shares closed yesterday at C$0.08, close to its 52-week low of C$0.07.
Read More on TSE:MMED:
- Mind Medicine enters exclusive license agreement with Catalent
- Rising High: Exclusive talk with mental healthcare company Numinus
- H.C. Wainwright sees ‘high’ odds of success for Mind Medicine Phase 2b trial
- FDA issues first draft guidance on clinical trials with psychedelic drugs
- FCM says receives ‘significant support’ from Mind Medicine shareholders at AGM
